Citius Pharmaceuticals, Inc. Proceeds from Lines of Credit
Citius Pharmaceuticals, Inc. (CTXR) reported Proceeds from Lines of Credit of $9.63 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromLinesOfCredit · last filed 2026-08-14
- 2026-06-30: Proceeds from Lines of Credit 9 month $9.63M.
| Period end | Proceeds from Lines of Credit 9 month |
|---|---|
| 2026-06-30 | $9.63M 10-Q · filed 2026-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |